{"id":"W4376114963","doi":"10.51731/cjht.2023.640","title":"Olaparib (Lynparza)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Reimbursement; Medicine; Oncology; Germline; Internal medicine; BRCA mutation; Adjuvant; Drug; Human Epidermal Growth Factor Receptor 2; Chemotherapy; Breast cancer; Gynecology; Cancer; Pharmacology; Political science; Genetics; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000473053,0.0002932297,0.0002711792,0.0006228345,0.0002889547,0.0009542066,0.0004020373,0.0005960632,0.0234868],"category_scores_gemma":[0.0006880019,0.0001002061,0.0003799113,0.0004573508,0.000260874,0.0004779085,0.0003995239,0.0008234837,0.006415549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001096843,"about_ca_system_score_gemma":0.00167104,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006041005,"about_ca_topic_score_gemma":0.01812813,"domain_scores_codex":[0.9997687,0.00004448491,0.00002873057,0.00004582069,0.00008408174,0.00002831791],"domain_scores_gemma":[0.9997522,0.0000504762,0.00006671996,0.00001085172,0.00008191917,0.00003777465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005101883,0.00005588149,0.0002808439,0.003569071,0.00005677963,0.0002179265,0.0000332057,0.0001854453,0.004801567,0.004142197,0.1097658,0.8763812],"study_design_scores_gemma":[0.0002250636,0.0003658128,0.001429442,0.001201518,0.00006270613,0.0009017407,0.00002691892,0.00009568749,0.002910942,0.000631122,0.9921359,0.00001316187],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.008359717,0.7540206,0.002260726,0.01055749,0.002414901,0.0003144279,0.002881743,0.0005504636,0.2186398],"genre_scores_gemma":[0.142,0.6731222,0.006416909,0.01909168,0.001238338,0.0003115603,0.005368292,0.00009193524,0.152359],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.0234868,"threshold_uncertainty_score":0.07857114,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06684353766478728,"score_gpt":0.3530063722913855,"score_spread":0.2861628346265982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}